Prothea Technologies offers a medical device that combines a Microendoscope with an Image Processing System to perform lung cancer biopsies and treatments in a single hospital visit. This technology reduces the time-to-treatment from weeks to minutes, improving patient outcomes and alleviating hospital resource pressures.
Funding
$13M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MRFounders
Product
Problem
Current lung cancer diagnosis often involves multiple procedures and can take weeks to complete, leading to delays in treatment initiation. This prolonged diagnostic process can increase patient anxiety and potentially worsen outcomes due to the time-sensitive nature of cancer treatment.
Solution
Prothea Technologies offers a medical device that integrates a microendoscope with an image processing system, enabling lung cancer biopsies and treatments to be performed during a single hospital visit. This technology significantly reduces the time-to-treatment, potentially improving patient outcomes and alleviating pressure on hospital resources. By combining diagnostic and therapeutic capabilities into one procedure, Prothea aims to streamline the lung cancer care pathway.
Target Audience
The primary target audience includes pulmonologists, oncologists, and interventional radiologists specializing in lung cancer diagnosis and treatment, as well as hospitals and cancer centers.
Features
- Integrated microendoscope for precise visualization of lung tissue.
- Advanced image processing system for real-time analysis and guidance.
- Single-visit biopsy and treatment capability.